{
  "docId": "019de072-a06b-75fe-abfc-06d6c9b36d69",
  "docSlug": "20a8e4b0fa87449fed1951c46c728b45",
  "documentTitle": "argenx SE | Results Presentation Deck | 21 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 21,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "comparison_table",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 28,
  "notes": "The table compares safety metrics including AE frequency, severity, and specific categories of interest.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-a06b-75fe-abfc-06d6c9b36d69/13",
  "deckHref": "/decks/019de072-a06b-75fe-abfc-06d6c9b36d69",
  "deckJsonHref": "/decks/019de072-a06b-75fe-abfc-06d6c9b36d69.json",
  "deckAnchorHref": "/decks/019de072-a06b-75fe-abfc-06d6c9b36d69#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.02,
        "w": 0.4,
        "x": 0.03,
        "y": 0.96
      },
      "kind": "disclaimer",
      "text": "*No SAEs were considered by investigators to be related to therapy",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5e9bd9c6-3a90-4707-8107-42cd923dab97",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.94,
        "x": 0.03,
        "y": 0.185
      },
      "kind": "table",
      "text": "Comparison of adverse events between VYVGART and Placebo groups.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "00ed3aa0-6369-4a2b-a806-5e41621d4add",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.9,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Safety and tolerability profile consistent with previous trials; First chronic dosing Phase 3 trial; Most AEs mild to moderate",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d39a8e0d-ba03-4c92-bd9d-ee365b923003",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "VYVGART Demonstrated Favorable Safety Profile",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f896131b-7704-4bf3-b631-3cfb939d1f91",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}